Follow Medasense’s accomplishments and news

NOL Pain Response Monitoring Secures Marketing Approval in Brazil

Medasense has announced that its NOL® pain response monitoring device (PMD-200) has been approved for marketing in Brazil by ANVISA, the Brazilian health regulatory agency.

An early user of the NOL in Brazil, Dr. José Luiz Gomes do Amaral, Professor and Chairman of the Department of Anesthesiology, Pain & Critical Care at Escola Paulista de Medicina Hospital São Paulo, stated: “The introduction of NOL monitoring in Brazil is an exciting development for me and my colleagues, as I believe this might be the breakthrough technology we have all been looking for to help us provide better pain medication treatment.”

Karine Moriya, CEO of J.G. Moriya, Medasense commercial partner in Brazil, commented: “Our network of influential surgeons and anaesthesiologists should allow us to bring this much-needed technology to Brazil’s advanced surgical facilities and we expect to perform the first NOL-guided surgeries in the coming weeks.”

Read the full press release!
English | Portuguese

Video Highlights

The essence of Medasense: Guiding critical care clinicians for optimal pain care

Meeting the challenge of intraoperative pain monitoring

Leading clinicians on the importance of monitoring the patient’s pain response level